SWOG clinical trial number
E1905
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia
Closed
Phase
Published
Abbreviated Title
Phase II Azacitidine +/- MS-275 for MDS, CML (Dysplastic), and AML with Multilineage Dysplasia
Activated
10/01/2006
Participants
Research committees
Leukemia
Treatment
Azacitidine
MS-275
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
CTSU/A042001
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
S1925
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
62% Accrual
Accrual
62%
Open
Phase
CTSU/AALL1821
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Activated
12/04/2020
Open